Synthesis and antimycobacterial evaluation of novel phthalazin-4- ylacetamides against log- and starved phase cultures: Research article

Chemical Biology and Drug Design

Volumn 75, Issue 4, 2010, Pages 381-391

  Sriram, Dharmarajan ^a   Yogeeswari, Perumal ^a   Senthilkumar, Palaniappan ^a   Sangaraju, Dewakar ^a   Nelli, Rohit ^a   Banerjee, Debjani ^a   Bhat, Pritesh ^a   Manjashetty, Thimmappa H ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Acetamides; Antimycobacterial activity; Antitubercular activity; Dormant tuberculosis; Isocitrate lyase enzyme; Phthalazinyl derivatives; Tuberculosis

Indexed keywords

2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (2 METHYL 3 CHLOROPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (2 TRIFLUOROMETHYLPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (2,4 DIMETHYLPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (2,6 DIMETHYLPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (4 BROMO 5 METHYLPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (4 BROMOPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (4 FLUOROPHENYL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (4 METHYLPYRIDIN 2 YL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (5 NITROTHIAZOL 2 YL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N (PYRIDIN 2 YL)ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N [2 CHLORO 5 (TRIFLUOROMETHYL)PHENYL]ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N [6 NITROBENZO(DEXTRO)THIAZOL 2 YL]ACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 1,2 DIHYDRO 1 OXOPHTHALAZIN 4 YL] N PHENYLACETAMIDE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 4 [2 (4 METHYLPIPERAZIN 1 YL) 2 OXOETHYL]PHTHALAZIN 1(2H)ONE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 4 [2 [4 (3 TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YL] 2 OXOETHYL]PHTHALAZIN 1(2H)ONE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 4 [2 [4 (4 BROMOPHENYL)PIPERAZIN 1 YL] 2 OXOETHYL]PHTHALAZIN 1(2H)ONE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 4 [2 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL] 2 OXOETHYL]PHTHALAZIN 1(2H)ONE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 4 [2 OXO 2 (4 PHENYLPIPERAZIN 1 YL)PHTHALAZIN 1(2H)ONE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 4 [2 OXO 2 (4 PIPERONOYL)PIPERAZIN 1 YL]ETHYL]PHTHALAZIN 1(2H)ONE; 2 [2 (4 BROMO 2 FLUOROBENZYL) 4 [2 OXO 2 (4 PYRIDIN 2 YL)PIPERAZIN 1 YL]ETHYL]PHTHALAZIN 1(2H)ONE; 3 NITROPROPIONIC ACID; ANTIMYCOBACTERIAL AGENT; CIPROFLOXACIN; ISOCITRATE LYASE; ISONIAZID; PHTHALAZINE DERIVATIVE; PHTHALIC ANHYDRIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIMYCOBACTERIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; FEMALE; LUNG; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUBERCULOSIS; VERO CELL;

ACETAMIDES; ANTITUBERCULAR AGENTS; BINDING SITES; CATALYTIC DOMAIN; COMPUTER SIMULATION; ISOCITRATE LYASE; MICROBIAL SENSITIVITY TESTS; PHTHALAZINES;

ANIMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 77449105835     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00947.x     Document Type: Article

References (41)

1. World Health Organization 2008) Global TB Control Report. World Health Organization, Geneva, Switzerland.
2. Zhang Y. (2005) The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 45 : 529 564.
3. Zhang Y., Mitchison D. (2003) The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7 : 6 21.
4. Kumar R.R., Perumal S., Senthilkumar P., Yogeeswari P., Sriram D. (2008) Discovery of antimycobacterial spiro-piperidin-4-ones: an atom economic, stereoselective synthesis, and biological intervention. J Med Chem 51 : 5731 5735.
5. Dinakaran M., Senthilkumar P., Yogeeswari P., China A., Nagaraja V., Sriram D. (2008) Synthesis, antimycobacterial activities and phototoxic evaluation of 5H-thiazolo[3,2-a]quinoline-4-carboxylic acid derivatives. Med Chem 4 : 482 491.
6. Dinakaran M., Senthilkumar P., Yogeeswari P., China A., Nagaraja V., Sriram D. (2008) Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. Bioorg Med Chem Lett 18 : 1229 1236.
7. Senthilkumar P., Dinakaran M., Banerjee D., Devakaram R.V., Yogeeswari P., China A., Nagaraja V. (2008) Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids. Bioorg Med Chem 16 : 2558 2569.
8. Dinakaran M., Senthilkumar P., Yogeeswari P., China A., Nagaraja V., Sriram D. (2008) Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5, 12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid. Bioorg Med Chem 16 : 3408 3418.
9. Dinakaran M., Senthilkumar P., Yogeeswari P., China A., Nagaraja V., Sriram D. (2008) Antimycobacterial and phototoxic evaluation of novel 6-fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid. Int J Antimicrob Agents 31 : 337 344.
10. Sriram D., Senthilkumar P., Dinakaran M., Yogeeswari P., China A., Nagaraja V. (2007) Antimycobacterial activities of novel 1-(cyclopropyl/tert- butyl/4-fluorophenyl)-1,4-dihydro- 6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. J Med Chem 50 : 6232 6239.
11. Sriram D., Yogeeswari P., Dinakaran M., Thirumurugan R. (2007) Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub) phenyl/pyridylthiourea endowed with high activity toward multi-drug resistant tuberculosis. J Antimicrob Chemother 59 : 1194 1196.
12. Kumar R.R., Perumal S., Senthilkumar P., Yogeeswari P., Sriram D. (2007) An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8- tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. Bioorg Med Chem Lett 17 : 6459 6462.
13. Sriram D., Yogeeswari P., Thirumurugan R., Pavana R.K. (2006) Discovery of newer antitubercular oxazolyl thiosemicarbazones. J Med Chem 49 : 3448 3450.
14. Vedejs E., Marth C.F. (1988) Mechanism of the Wittig reaction: the role of substituents at phosphorus. J Am Chem Soc 110 : 3948 3958.
15. Kangani C.O., Master H.E. (1998) Preparation of 1-aminoanthraquinone-2- carbohydrazide, 1.3.4-oxadiazoles, pyrazoles, pyrimidines and phthalazines. Ind J Chem 37 : 778 783.
16. National Committee for Clinical Laboratory Standards 1995) Antimycobacterial Susceptibility Testing for Mycobacterium tuberculosis. Proposed standard M24-T. Villanova, PA : National Committee for Clinical Laboratory Standards.
17. Katoch V.M. (2004) Infections due to non-tuberculous mycobacteria (NTM). Ind J Med Res 120 : 290 304.
18. Schreiber J., Burkhardt U., Rusch-Gerdes S., Amthor M., Richter E., Zugehor M., Rosahl W., Ernst M. (2001) Non-tubercular mycobacterial infection of the lungs due to Mycobacterium smegmatis. Pneumologie 55 : 238 243.
19. Geiss H.K., Feldhues R., Niemann S., Nolte O., Rieker R. (2005) Landouzy septicemia (sepsis tuberculosa acutissima) due to Mycobacterium microti in an immunocompetent man. Infection 33 : 393 396.
20. Hachem R., Raad I., Rolston K.V., Whimbey E., Katz R., Tarrand J., Libshitz H. (1996) Cutaneous and pulmonary infections caused by Mycobacterium vaccae. Clin Infect Dis 23 : 173 175.
21. Spiegl P.V., Feiner C.M. (1994) Cutaneous and pulmonary infections caused by Mycobacterium vaccae. Foot Ankle Int 15 : 680 683.
22. O'Brien R.J., Geiter L.j., Snider D.E. (1987) The epidemiology of nontuberculous mycobacteria disease in the United States; results from a national survey. Am Rev Respir Dis 135 : 1007 1014.
23. Tabatabaei N., Stout J., Goldschmidt-Clermont P., Murdoch D. (2007) Central nervous system infection and cutaneous lymphadenitis due to Mycobacterium kansasii in an immunocompetent patient. Infection 35 : 291 294.
24. Xie Z., Siddiqi N., Rubin E.J. (2005) Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 49 : 4778 4780.
25. Wayne L.G., Sohaskey C.D. (2001) Non-replicating persistence of Mycobacterium tuberculosis. Ann Rev Microbiol 55 : 139 163.
26. Betts J.C., Lukey P.T., Robb L.C., Mc Adam R.A., Duncan K. (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43 : 717 731.
27. Hu Y., Coates A.R.M., Mitchison D.A. (2003) Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 : 653 657.
28. Mc Dermott W. (1958) Microbial persistence. Yale J Biol Med 30 : 257 291.
29. Zhang Y. (2004) Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci 9 : 1136 1156.
30. O'Brien R.J., Nunn P.P. (2001) The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med 163 : 1055 1058.
31. Murphy D.J., Brown J.R. (2008) Novel drug target strategies against Mycobacterium tuberculosis. Curr Opin Microbiol 11 : 422 427.
32. Mc Kinney J.D. (2000) Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406 : 735 738.
33. Glickman M.S. (2000) A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 5 : 717 727.
34. Dahl J.L. (2003) The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci USA 100 : 10026 10031.
35. Park H.D. (2003) Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 48 : 833 843.
36. Bentrup K.H.Z., Miczak A., Swenson D.L., Russell D.G. (1999) Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 181 : 7161 7167.
37. Bai B., Xie J.P., Yan J.F., Wang H., Hu C. (2006) A high throughput screening approach to identify isocitrate lyase inhibitors from traditional chinese medicine sources. Drug Dev Res 67 : 818 823.
38. Sharma V., Sharma S., Kerstin H.B., McKinney J.D., Russell D.G., Jacobs W.R., Sacchettini J.C. (2000) Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol 8 : 633 668.
39. Gundersen L.L., Nissen-Meyer J., Spilsberg B. (2002) Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines. J Med Chem 45 : 1383 1386.
40. Sriram D., Yogeeswari P., Basha S.J., Radha D.R., Nagaraja V. (2005) Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem 13 : 5774 5778.
41. Thomsen R., Christensen M.H. (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49 : 3315 3321.